Jade Biosciences (JBIO) Non-Current Assets (2020 - 2026)
Jade Biosciences (JBIO) posted Non-Current Assets of $916000.0 for Q1 2026, down 5.08% on a QoQ basis from $965000.0 in Q4 2025, and up 472.5% year-over-year from $160000.0 in Q1 2025.
Jade Biosciences (JBIO) Non-Current Assets (2020 - 2026) Analysis & Trends
Jade Biosciences' Non-Current Assets history runs 7 years deep, the most recent figure standing at $916000.0 for Q1 2026.
- Quarterly Non-Current Assets rose 472.5% year-over-year to $916000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 13.89% YoY) and the FY2025 annual result came in at $965000.0, down 69.32% from the prior year.
- Non-Current Assets was $916000.0 for Q1 2026 at Jade Biosciences, down from $965000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $3.8 million in Q1 2023 and bottomed at $160000.0 in Q1 2025.
- A 5-year average of $2.1 million and a median of $2.2 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets tumbled 95.53% — and 2026, when it jumped 472.5%.
- Jade Biosciences' Non-Current Assets stood at $3.8 million in 2022, then slipped by 16.27% to $3.2 million in 2023, then retreated by 1.29% to $3.1 million in 2024, then plunged by 69.32% to $965000.0 in 2025, then slipped by 5.08% to $916000.0 in 2026.
- Business Quant data shows JBIO's Non-Current Assets at $916000.0 in Q1 2026, $965000.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Jade Biosciences | 16.25 Mn | 16.25 Mn | - | 916,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 916,000.00 |
| Dec 31, 2025 | 965,000.00 |
| Sep 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 984,000.00 |
| Mar 31, 2025 | 160,000.00 |
| Dec 31, 2024 | 3.15 Mn |
| Sep 30, 2024 | 354,000.00 |
| Jun 30, 2024 | 934,000.00 |
| Mar 31, 2024 | 3.58 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 3.29 Mn |
| Mar 31, 2023 | 3.82 Mn |
| Dec 31, 2022 | 3.81 Mn |
| Sep 30, 2022 | 2.50 Mn |
| Jun 30, 2022 | 2.24 Mn |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 1.03 Mn |
| Sep 30, 2021 | 1.02 Mn |
| Jun 30, 2021 | 3.13 Mn |